KYTX · NASDAQ · Biotechnology

Kyverna Therapeutics (KYTX)

Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.

$7.05
vs last close−0.46 (−6.09%)